Paola Carolina Torres Hernández

Dr. Paola Carolina Torres Hernández

Laboratory of Immunology, University of Guadalajara
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
JNJose Javier Morales Nuñez
Jose Javier Morales Nuñez
José Francisco Muñoz-ValleJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
CMCarlos Meza-López
Carlos Meza-López
LWLin-Fa Wang
Lin-Fa Wang
Andrea Carolina Machado-SulbaranAndrea Carolina Machado-Sulbaran
Andrea Carolina Machado-Sulbaran
JHJorge Hernández-Bello
Jorge Hernández-Bello
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the first to be authorized in the USA and Mexico (11 December 2020). This study evaluated the efficacy of this vaccine on antibody production with neutralizing capacity and its side effects in healthcare workers with and without prior SARS-CoV-2 infection and in a group of unvaccinated individuals with prior COVID-19. The main findings are the production of 100% neutralizing antibodies in both groups after the second dose, well-tolerated adverse effects, the possible presence of immunosenescence, and finally, we support that a single dose of this vaccine in individuals with prior COVID-19 would be sufficient to achieve an immunization comparable to people without prior COVID-19 with a complete vaccination program (2 doses).

20 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
JHJorge Hernández-Bello
Jorge Hernández-Bello
JNJose Javier Morales Nuñez
Jose Javier Morales Nuñez
Andrea Carolina Machado-SulbaranAndrea Carolina Machado-Sulbaran
Andrea Carolina Machado-Sulbaran
SPSaúl Alberto Díaz Pérez
Saúl Alberto Díaz Pérez
Paola Carolina Torres HernándezPaola Carolina Torres Hernández
Paola Carolina Torres Hernández
José Francisco Muñoz-ValleJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people (117 with prior COVID-19 and 229 without prior COVID-19) vaccinated with Ad5-nCoV were recruited. The percentage of neutralizing antibodies against SARS-CoV-2 (Surrogate Virus Neutralization Test) and antibodies against Ad5 (ADV-Ad5 IgG ELISA) were quantified pre and post-vaccination effects. The Ad5-nCoV vaccine induces higher neutralizing antibodies percentage in individuals with prior COVID-19 than those without prior COVID-19 (median [IQR]: 98% [97–98.1] vs. 72% [54–90], respectively; p < 0.0001). Furthermore, a natural infection (before vaccination) induces more neutralizing antibodies percentage than immunized individuals without prior COVID-19 (p < 0.01). No patient had vaccine-severe adverse effects. The age, antidepressant, and immunosuppressive treatments, reactogenicity, and history of COVID-19 are associated with impaired antibody production. The anti-Ad5 antibodies increased after 21 days of post-vaccination in all groups (p < 0.01). We recommend the application of a booster dose of Ad5-nCoV, especially for those individuals without previous COVID-19 infection. Finally, the induction of anti-Ad5 antibodies after vaccination should be considered if a booster with the same vaccine is planned.

21 October 2022 in Immunology Letters
Verified
Journal Article
Closed access
JNJose Javier Morales Nuñez
Jose Javier Morales Nuñez
JMJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
Andrea Carolina Machado-SulbaranAndrea Carolina Machado-Sulbaran
Andrea Carolina Machado-Sulbaran
SPSaúl Alberto Díaz Pérez
Saúl Alberto Díaz Pérez
Paola Carolina Torres HernándezPaola Carolina Torres Hernández
Paola Carolina Torres Hernández
JHJorge Hernández-Bello
Jorge Hernández-Bello

4 August 2022 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
JNJose Javier Morales Nuñez
Jose Javier Morales Nuñez
MGMariel García-Chagollán
Mariel García-Chagollán
José Francisco Muñoz-ValleJosé Francisco Muñoz-Valle
José Francisco Muñoz-Valle
SPSaúl Alberto Díaz Pérez
Saúl Alberto Díaz Pérez
Paola Carolina Torres HernándezPaola Carolina Torres Hernández
Paola Carolina Torres Hernández
JHJorge Hernández-Bello
Jorge Hernández-Bello
Purpose: Understanding the humoral immune response dynamics carried out by B cells in COVID-19 vaccination is little explored; therefore, we analyze the changes induced in the different cellular subpopulations of B cells after vaccination with BNT162b2 (Pfizer-BioNTech). Methods: This prospective cohort study evaluated thirty-nine immunized health workers (22 with prior COVID-19 and 17 without prior COVID-19) and ten subjects not vaccinated against SARS-CoV-2 (control group). B cell subpopulations (transitional, mature, naïve, memory, plasmablasts, early plasmablast, and double-negative B cells) and neutralizing antibody levels were analyzed and quantified by flow cytometry and ELISA, respectively. Results: The dynamics of the B cells subpopulations after vaccination showed the following pattern: the percentage of transitional B cells was higher in the prior COVID-19 group (p < 0.05), whereas virgin B cells were more prevalent in the group without prior COVID-19 (p < 0.05), mature B cells predominated in both vaccinated groups (p < 0.01), and memory B cells, plasmablasts, early plasmablasts, and double-negative B cells were higher in the not vaccinated group (p < 0.05). Conclusion: BNT162b2 vaccine induces changes in B cell subpopulations, especially generating plasma cells and producing neutralizing antibodies against SARS-CoV-2. However, the previous infection with SARS-CoV-2 does not significantly alter the dynamics of these subpopulations but induces more rapid and optimal antibody production.